International Reference Pricing

The tool for full understanding of International Reference Pricing:

IRP Tool Master Tool

Negotiate and change prices with a full understanding of their effect in referencing countries.

Set strategy confidently using transparent, detailed analysis – price and net revenue forecasting – conditioned by pricing regulations and practices globally. A tool for launch planning optimization and in-market mitigation.

No International Reference Pricing for drugs in the US – good news for patients in the US and worldwide

No International Reference Pricing for drugs in the US

The US Government just published its “Comprehensive Plan for Addressing High Drug Prices”. It lists a number of initiatives and ideas, but does NOT mention is International Reference Pricing – and this is good news for patients in the US and worldwide (and for manufacturers, too). – Read the Akceso Advisors reflection on a latest development in the US pharmaceuticals market based on Akceso Advisors’ research related to the impact of International Reference Pricing (IRP) on patient access and innovation.

The best tools for your challenges.

Get in touch with us and schedule a demo.

Error: Contact form not found.

Join our mailing list!

The PRiMA Headlines Newsletter provides a monthly overview of developments in Pricing, Reimbursement and Market Access developments across the globe. Since its launch in June 2015 we have covered more than 5,000 stories from over 100 countries.

Scroll to Top